These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

937 related items for PubMed ID: 26133315

  • 1. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC, Fiorenza MA, Estrada SJ.
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [Abstract] [Full Text] [Related]

  • 2. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [Abstract] [Full Text] [Related]

  • 3. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
    Sucher AJ, Chahine EB, Cogan P, Fete M.
    Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
    [Abstract] [Full Text] [Related]

  • 4. Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
    Bassetti M, Righi E.
    Future Microbiol; 2015 Sep; 10(2):151-60. PubMed ID: 25689527
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN.
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [Abstract] [Full Text] [Related]

  • 6. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
    Scott LJ.
    Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849
    [Abstract] [Full Text] [Related]

  • 7. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL, Mahoney MV, Hirsch EB.
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [Abstract] [Full Text] [Related]

  • 8. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK.
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [Abstract] [Full Text] [Related]

  • 9. Ceftolozane-tazobactam: A new-generation cephalosporin.
    Cluck D, Lewis P, Stayer B, Spivey J, Moorman J.
    Am J Health Syst Pharm; 2015 Dec 15; 72(24):2135-46. PubMed ID: 26637512
    [Abstract] [Full Text] [Related]

  • 10. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
    Eckmann C, Solomkin J.
    Expert Opin Pharmacother; 2015 Feb 15; 16(2):271-80. PubMed ID: 25529765
    [Abstract] [Full Text] [Related]

  • 11. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
    Maseda E, Aguilar L, Gimenez MJ, Gilsanz F.
    Expert Rev Anti Infect Ther; 2014 Nov 15; 12(11):1311-24. PubMed ID: 25139127
    [Abstract] [Full Text] [Related]

  • 12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb 15; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.
    Antimicrob Agents Chemother; 2016 Jan 15; 60(1):515-21. PubMed ID: 26552975
    [Abstract] [Full Text] [Related]

  • 14. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS, Farrell DJ, Flamm RK, Jones RN.
    J Infect; 2014 Sep 15; 69(3):266-77. PubMed ID: 24780763
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M, García-Castillo M, Bofarull AM, Cantón R, CENIT Study Group.
    Int J Antimicrob Agents; 2015 Nov 15; 46(5):502-10. PubMed ID: 26315199
    [Abstract] [Full Text] [Related]

  • 16. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
    Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.
    Int J Antimicrob Agents; 2017 Jan 15; 49(1):25-30. PubMed ID: 27931793
    [Abstract] [Full Text] [Related]

  • 17. Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.
    Giancola SE, Mahoney MV, Bias TE, Hirsch EB.
    Ther Clin Risk Manag; 2016 Jan 15; 12():787-97. PubMed ID: 27279744
    [Abstract] [Full Text] [Related]

  • 18. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C.
    Clin Infect Dis; 2015 May 15; 60(10):1462-71. PubMed ID: 25670823
    [Abstract] [Full Text] [Related]

  • 19. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
    Melchers MJ, van Mil AC, Mouton JW.
    Antimicrob Agents Chemother; 2015 Aug 15; 59(8):4521-5. PubMed ID: 25987635
    [Abstract] [Full Text] [Related]

  • 20. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ, Sader HS, Flamm RK, Jones RN.
    Int J Antimicrob Agents; 2014 Jun 15; 43(6):533-9. PubMed ID: 24856078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.